Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care
DSpace/Manakin Repository
Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care
| Title: | Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care |
| Author: |
Wang, Shuqi; Zhao, Xiaohu; Khimji, Imran; Akbas, Ragip; Qiu, Weiliang; Edwards, Dale; Cramer, Daniel William; Ye, Bin; Demirci, Utkan
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Wang, ShuQi., Xiaohu Zhao, Imran Khimji, Ragip Akbas, Weiliang Qiu, Dale Edwards, Daniel W. Cramer, Bin Ye, and Utkan Demirci. 2011. “Integration of Cell Phone Imaging with Microchip ELISA to Detect Ovarian Cancer HE4 Biomarker in Urine at the Point-of-Care.” Lab Chip 11 (20): 3411. doi:10.1039/c1lc20479c. |
| Full Text & Related Files: |
nihms504867.pdf (1.233Mb; PDF) 
|
| Abstract: | Ovarian cancer is asymptomatic at early stages and most patients present with advanced levels of disease. Lack of cost-effective methods that can achieve frequent, simple and non-invasive testing hinders early detection and causes high mortality in ovarian cancer patients. Here, we report a simple and inexpensive microchip ELISA-based detection module that employs a portable detection system, i.e., a cell phone/charge-coupled device (CCD) to quantify an ovarian cancer biomarker, HE4, in urine. Integration of a mobile application with a cell phone enabled immediate processing of microchip ELISA results, which eliminated the need for a bulky, expensive spectrophotometer. The HE4 level detected by a cell phone or a lensless CCD system was significantly elevated in urine samples from cancer patients (n = 19) than normal healthy controls (n = 20) (p < 0.001). Receiver operating characteristic (ROC) analyses showed that the microchip ELISA coupled with a cell phone running an automated analysis application had a sensitivity of 89.5% at a specificity of 90%. Under the same specificity, the microchip ELISA coupled with a CCD had a sensitivity of 84.2%. In conclusion, integration of microchip ELISA with cell phone/CCD-based colorimetric measurement technology can be used to detect HE4 biomarker at the point-of-care (POC), paving the way to create bedside technologies for diagnostics and treatment monitoring. |
| Published Version: | doi:10.1039/c1lc20479c |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767574/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:27332637 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [20474]
Contact administrator regarding this item (to report mistakes or request changes)
